- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Post USFDA warning letter, Amazon removing 7 unapproved eye drops from its e-commerce platform
The eye drops flagged in the letter to Amazon include Similasan Pink Eye Relief, Can-C Eye Drops, Optique 1 Eye Drops and OcluMed Eye Drops, among others.
Amazon said on Wednesday it was in the process of removing seven unapproved eye drops from its e-commerce platform following a warning letter from the U.S. health regulator earlier this week.The products in question have been investigated and are in the process of being removed, a company spokesperson said.The U.S. Food and Drug Administration (FDA) on Monday sent a warning letter to Amazon...
Amazon said on Wednesday it was in the process of removing seven unapproved eye drops from its e-commerce platform following a warning letter from the U.S. health regulator earlier this week.
The products in question have been investigated and are in the process of being removed, a company spokesperson said.
The U.S. Food and Drug Administration (FDA) on Monday sent a warning letter to Amazon for selling eye drops which have not been recognized as safe and effective in providing temporary relief from symptoms such as excessive watery discharge, redness, burning and pink eye.
The eye drops flagged in the letter to Amazon include Similasan Pink Eye Relief, Can-C Eye Drops, Optique 1 Eye Drops and OcluMed Eye Drops, among others.
The FDA has warned consumers against using 26 over-the-counter eye drops due to risk of infection and some cases of possible vision loss.
Read also: USFDA warns against use of 26 over-the-counter eye drop products
The health agency also sent warning letters to eight other companies in September, including pharmacy giants CVS Health and Walgreens Boots Alliance, against manufacturing or marketing of certain unapproved eye products.
Ruchika Sharma joined Medical Dialogue as an Desk Editor for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751